State-Backed Investor Maps the True Costs of Green Farming Transition
Amsterdam, Wednesday 29 July 2026
Dutch impact investor Invest-NL has launched an initiative to map the exact financial gaps hindering farmers from transitioning to eco-friendly regenerative agriculture.
Bridging the Agrifood Funding Gap
The transition to regenerative farming is critical for improving soil quality, biodiversity, water management, and climate resilience in the Netherlands [1]. However, agricultural entrepreneurs face substantial hurdles, including the need for new machinery, operational adjustments, and temporary yield reductions during the transition phase [1]. To address this, Dutch state-backed impact investor Invest-NL has partnered with Wageningen Social & Economic Research to conduct a comprehensive analysis of the financing gap [1]. This collaboration aims to establish clear definitions, indicators, scenarios, and calculation models to systematically understand the financial requirements of sustainable farming [1].
Developing Tailored Capital Models
Currently, there is a lack of systematic insight into the exact capital requirements of farmers during their transition period, which hinders large-scale adoption [1]. Invest-NL’s broader initiative seeks to model these financial needs to determine what types of capital—such as working capital, risk-sharing instruments, or direct investments—best suit different stages of the ecological transition [1]. Senior Business Development Manager Nina Waldhauer is actively leading efforts to collaborate with financial institutions, policymakers, and agricultural experts to co-create these practical solutions [1].
Catalysing MedTech and Lab-to-Market Transitions
Beyond agrifood tech, the Dutch impact investor is also actively supporting the Life Sciences and Health (LSH) sector to bring laboratory breakthroughs to clinical markets. In a recent development, Invest-NL committed €5 million to Eindhoven-based MedTech pioneer Xeltis [3]. This contribution is part of a larger €20.5 million funding round led by Horizon 3 Healthcare, meaning Invest-NL supplied approximately 24.39% of the total round [3]. Xeltis specialises in developing restorative medical implants that leverage endogenous tissue restoration, enabling the patient’s body to naturally grow new, living blood vessels [3][GPT].
Scaling Clinical Solutions for Patients
The newly secured capital is designated to scale up the production of Xeltis’s aXess™ vascular graft and expand its clinical availability across Europe [3]. For patients undergoing kidney dialysis, this technology represents a significant leap forward, potentially reducing the frequency of infections and surgical interventions compared to traditional synthetic grafts [3][GPT]. By intervening at critical growth phases, state-backed capital ensures that complex medical technologies successfully navigate the challenging transition from clinical trials to commercial markets [3].
De-risking Early-Stage Clean Technology
Invest-NL’s strategy of addressing early-stage financial bottlenecks extends to deep-tech and geothermal energy projects as well. High initial costs and substantial geological risks often stall geothermal initiatives during their early development phases [2]. To resolve these market failures, Invest-NL, Energie Beheer Nederland (EBN), and Geothermie Nederland commissioned financial consultancy Fakton to research viable financial instruments [2]. The resulting analysis proposes four specific instruments designed to deploy public funds to mobilise private investments, accelerating the deployment of sustainable heat infrastructure across the Netherlands [2].